Evidence map›Paper›PMID 39302578›Full record

ArticleBreast cancer research and treatment2025

Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study.

Julie A Schmidt, Cathrine F Hjorth, Dóra K Farkas, Per Damkier, Søren Feddersen, Stephen Hamilton-Dutoit, Bent Ejlertsen, Timothy L Lash, Thomas P Ahern, Deirdre Cronin-Fenton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julie A SchmidtDepartment of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark. js@clin.au.dk.ORCID http://orcid.org/0000-0002-7733-8750
Cathrine F HjorthDepartment of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.ORCID http://orcid.org/0000-0003-4378-8531
Dóra K FarkasDepartment of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.ORCID http://orcid.org/0000-0002-8577-048X
Per DamkierDepartment of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.ORCID http://orcid.org/0000-0003-0591-7187
Søren FeddersenDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.ORCID http://orcid.org/0000-0003-3262-3299
Stephen Hamilton-DutoitDepartment of Clinical Medicine and Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-2158-3885
Bent EjlertsenDanish Breast Cancer Group, Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-8761-714X
Timothy L LashDepartment of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.ORCID http://orcid.org/0000-0002-5240-5195
Thomas P AhernDepartment of Surgery, The Robert Larner, M.D. College of Medicine, The University of Vermont, Burlington, VT, USA.ORCID http://orcid.org/0000-0003-0440-8727
Deirdre Cronin-FentonDepartment of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.ORCID http://orcid.org/0000-0001-9738-2284

Funding

New and integrated perspectives on modification of tamoxifen effectivenessR01CA166825 · NCI · EMORY UNIVERSITY · PI LASH, TIMOTHY L. · 2013 to 2017
$2.8M
Dansk Kræftforsknings Fond FID1839672Kræftens Bekæmpelse R327-A19070Kræftens Bekæmpelse R359-A21368Lundbeck Foundation R167-2013-15861NCI NIH HHS R01 CA166825Novo Nordisk Fonden NNF19OC0058710US National Cancer Institute R01CA166825
6 · The paper itself

Abstract

purposeBreast cancer patients' need for social benefits may increase following taxane-based chemotherapy, due to long-lasting side effects. Specific single nucleotide polymorphisms (SNPs) may mediate such side effects. We investigated the association between SNPs related to taxane metabolism, transport, toxicity, or DNA and neural repair, and receipt of social benefits.

methodsFrom the Danish Breast Cancer Group, we identified premenopausal women diagnosed with stage I-III breast cancer during 2007-2011 and treated with docetaxel-based chemotherapy. We genotyped 21 SNPs from archived breast tumors using TaqMan assays. We ascertained social benefit payments from 1 year before to 5 years after diagnosis, using nationwide, administrative registry data. For each week, we categorized women as receiving health-related benefits (including sick leave and disability pension), labor market-related benefits (including unemployment benefits), or as being self-supporting. We computed rate ratios (RRs) of social benefit receipt for variant carriers (heterozygotes plus homozygotes) vs. non-carriers, using negative binominal regression with robust variance estimation.

resultsAmong 2430 women, 12% received health-related benefits before diagnosis, 80% at diagnosis, and ~ 24% 2 to 5 years after diagnosis. Labor market-related benefits were uncommon (3-6%). All RRs were near-null and/or imprecise.

conclusionWe found no clinically meaningful impact of the selected SNPs on social benefit receipt among premenopausal breast cancer survivors treated with docetaxel.

Indexed as

Breast NeoplasmsPolymorphism, Single NucleotideAdultCohort StudiesDenmarkDocetaxelFemaleGenotypeHumansMiddle AgedNeoplasm StagingPremenopauseDocetaxelBreast cancerSingle-nucleotide polymorphismsSocial benefitsSurvivorshipTaxane

Identifiers

PMID39302578
PMCPMC11785639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.